T. Ebina1, A. Sato1, K. Umezu1, H. Aso1, N. Ishida1, H. Seki2, T. Tsukamoto2, S. Takase2, S. Hoshi3, and M. Ohta4

1Department of Bacteriology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Sendai 980, Japan
2Department of Neurology, Institute of Brain Research, Tohoku University School of Medicine, Sendai 980, Japan
3Faculty of Agriculture Tohoku University, Sendai 980, Japan
4Kawatabi Farm, Faculty of Agriculture Tohoku University, Narugo 989-67, Japan

Abstract. Previous virological and immunological studies have suggested that multiple sclerosis (MS) is an auto-immune disease triggered by a virus infection. In order to inhibit the growth of measles virus in the patient’s jejunum, we obtained an IgA-rich cow colostrum containing anti-measles lactoglobulin resistant to proteases. This colostrum was orally administered to patients with MS to investigate its effect on the course of the disease.

Measles-positive antibody colostrum was orally administered every morning to 15 patients with MS at a daily dosage of 100 ml for 30 days. Similarly, measles-negative antibody (< 8) control colostrum was orally administered to 5 patients. As a clinical assessment, disability scores developed by the International Federation of Multiple Sclerosis Societies were used. As a result, of 7 high NT titre (512-5120) anti-measles colostrum recipients 5 patients improved and 2 remained unchanged. Among 8 low NT titre (8-32) anti-measles colostrum recipients 5 patients improved and 3 remained unchanged. However, of 5 negative NT titre (< 8) colostrum recipients 2 patients remained unchanged and 3 worsened. No side-effects were observed in colostrum recipients. These findings suggest the efficacy of orally administered anti-measles colostrum in improving the condition of MS patients (P < 0.05).

Introduction

Following the methods of Prasad et al. [7], we were able to rescue measles virus antigens from the jejunum of 7 of 11 multiple sclerosis (MS) patients in a clinically stable state by the cell fusion technique using polyethylene glycol [3]. It was hypothesized that the manifestation of measles virus in jejunum cells at certain times, probably at exacerbation, by an unknown mechanism results in the infection of nascent T-lymphocytes [9] and the modification of T-cell membranes. Then the modified T-lymphocytes can be recognized as foreign bodies and anti-modified T-lymphocyte sera will be produced as
auto-antibodies. These auto-antibodies, frequently found in the sera from MS patients in the exacerbation state, were proved to be detectable as lymphocytotoxic antibodies (10/12 patients, 83%) [10]. As the cell membrane of T-lymphocytes shares common antigens with human brain tissue [1, 2, 12], it is likely that the virus-induced lymphocytotoxic antibodies would further cross-react with brain cell membranes, leading to the immunopathological demyelination in the central nervous system of MS patients. We propose briefly that MS is an auto-immune disease triggered by a virus infection. The purpose of this paper is to confirm our hypothesis and to develop a new treatment for MS. Therefore, in order to inhibit the growth of measles virus in the patient’s jejunum at exacerbation, we obtained an IgA-rich colostrum containing anti-measles neutralizing antibodies, which are resistant to proteases, and orally administered it to patients with MS.

Materials and methods

_Preparation of anti-measles cow colostrum._ Eight-month-pregnant Holstein cows were immunized subcutaneously with the Schwarz strain of measles virus (10^{5.6} TCID_{50} / ml x 5 ml) 5 times at 10-day intervals until calving. Colostrum collected on the first 3 days (10 l, each) was immediately cooled and stored. Butter fat was removed by a cream separator and bacteria and red blood cells were removed by three centrifugations at 10 000 g for 30 min. Colostral non-fat milk was checked for bacteria (less than 30 000/ml) and _E. coli_ before being approved for drinking by the Sendai Municipal Institute of Hygiene and then frozen in 100-ml units until administration.

_Purification of immunoglobulin from cow colostrum._ After casein had been removed by acid precipitation (pH 4.6), colostral whey was applied to a DEAE cellulose column (DE_{52}, 1.8 x 28 cm) and eluted with 0.01 M phosphate buffer (pH 7.8). Each fraction was assayed for bovine IgG and bovine IgA by single radial immunodiffusion using antibovine serum IgG and antibovine serum IgA (Miles Laboratories, Inc., USA). After rechromatography of DE_{52}, the preparation containing IgG was applied to a Sephadex G-200 column (2 x 90 cm) and eluted with 0.1 M Tris-HCl buffer (pH 8.0) containing 0.2 M NaCl. After rechromatography of G-200, purified IgG was finally obtained. The preparation containing IgG was reapplied to a G-200 column. IgA fractions were then applied to a protein A CL4B affinity column and eluted with 0.1 M phosphate buffer (pH 8.0). After G-200 gel filtration, purified IgA was finally obtained. Both purified IgG and IgA showed a single precipitation band in agar diffusion.

_Patients._ Included in this study were 20 patients (5 males and 15 females) aged 9—40 years with definite MS as defined by the Schumacher Committee criteria [8]. The duration of the disease prior to entering the study varied from 1.0 to 9.5 years.

_Clinical assessment._ For a clinical assessment, disability scores adopted by the International Federation of Multiple Sclerosis Societies (IFMSS) and listed as the Minimal Record of Disability were used. The Minimal Record of Disability contains data with which comparisons can be made between one MS centre and another or between one
country and another. The Multiple Sclerosis Minimal Record of Disability consists of five sections: demographic information, functional systems, the disability status scale in MS, incapacity status and environmental status. For this report, the data for functional systems and the disability status scale were used. In evaluating functional systems, ratings are based on the results of standard neurological examinations (pyramidal, cerebellar, brain-stem, sensory, bowel and bladder, visual and mental functions). For the disability status scale, scoring is based on the functional systems rating on a 10-point scale.

Results

Characterization of anti-measles colostrum

Neutralizing antibody (NT) titres of cow colostrums to measles virus and HAI titre of cow serum are given in Table 1, where NT titres were measured using an Edmonston strain of measles and Vero cells. Also Table 2 shows the contents of IgA and IgG in colostral non-fat milk. It is clear that 1st day colostrum contains the greatest amount of lactoglobulins with the highest NT titre when compared with 2nd and 3rd day colostrums. Market milk contains few lactoglobulins and no neutralizing antibodies to measles virus. Therefore, we studied the effect of the 1st day colostrum on altering the course of MS.

| Cow no. | Year | Milking (day) | NT titre | HAI |
|---------|------|---------------|----------|-----|
| 253     | 1981 | 1st           | <8       |     |
|         |      | 2nd           | <8       | <8  |
|         |      | 3rd           | <8       |     |
|         | 1982 | 1             | 32       |     |
|         |      | 2             | 16       | 8   |
|         |      | 3             | 8        |     |
|         | 1983 | 1             | 6400     | 64  |
|         |      | 2             | 6400     |     |
|         |      | 3             | 6400     |     |
| 200     | 1980 | 1st           | <8       |     |
|         |      | 2nd           | <8       | <8  |
|         |      | 3rd           | <8       |     |
|         | 1981 | 1             | 64       |     |
|         |      | 2             | 32       | 8   |
|         |      | 3             | 32       |     |
|         | 1982 | 1             | 4096     | 256 |
|         |      | 2             | 2048     |     |
|         |      | 3             | 512      |     |
|         | 1983 | 1             | 3200     |     |
|         |      | 2             | 3200     | 128 |
|         |      | 3             | 1600     |     |
Table 2. Contents of immunoglobulins in cow colostrum (mean of 12 colostrums, mean ± SD)

| Milking (day) | IgA (mg/100 ml) | IgG (mg/100 ml) | IgM (mg/100 ml) |
|---------------|----------------|----------------|----------------|
| 1st           | 292 ± 15       | 3023 ± 121     | 167 ± 12       |
| 2nd           | 125 ± 11       | 1574 ± 67      | 47 ± 7         |
| 3rd           | 55 ± 5         | 631 ± 32       | 14 ± 3         |

Table 3. NT titre of purified IgG and IgA to measles virus

|                    | Colostrum | Purified IgG | Purified IgA |
|--------------------|-----------|--------------|--------------|
| Ig concentration (mg/ml) | 67         | 5.4          | 1.5          |
| NT titre to measles | 16         | 8            | 16           |
| Specific activity (/mg Ig) | 0.24       | 1.5          | 10.7         |

Next, in order to characterize an effective Ig component having anti-measles neutralizing antibodies in colostrum, IgG and IgA were purified as described in Materials and methods. As shown in Table 3, the neutralizing activity of IgG and IgA against measles virus (Edmonston strain) was 1:1.5/mg and 1:10.7/mg respectively. Therefore, it seems that the neutralizing activity of IgG in colostrum is quantitatively dependent (Table 2) and that IgA is important qualitatively for inhibiting measles virus growth in the jejunum.

As for the stability of colostrum's neutralizing activity against proteases, we reported in a previous paper that treatment with trypsin (100–800 μg/ml) for 1 h did not affect the neutralizing titres [4].

Clinical effect of anti-measles colostrum on MS

Three kinds of cow colostrums were used; a high NT titre to measles virus (512-5120), a low NT titre to measles virus (8-32), and a negative NT titre to measles virus (< 8). A total of 20 MS patients were orally given 100 ml of IgA-rich colostrum every morning for 30 days. For each patient, the change in disability scores before and after the oral administration of colostrum was compared. As shown in Table 4, of 7 high NT titre anti-measles colostrum recipients 5 patients improved and 2 remained unchanged. As summarized in Table 5, anti-measles colostrum significantly improved the condition of MS patients (P < 0.05).
### Table 4. Clinical assessment by disability scores in MS patients treated with anti-measles colostrum

| Case | Age | Sex | Disability scores Before colostrum administration | Disability status scale | Disability scores After colostrum administration | Clinical assessment |
|------|-----|-----|-----------------------------------------------------|-------------------------|-----------------------------------------------|---------------------|
| OM   | 32  | Female | Functional systems: pyramidal function 2, cerebellar function 2 | (6)                       | (3)                                      | Improved           |
|      |     |        | Functional systems: sensory function 1, bladder function 1 |                          |                                            |                     |
|      |     |        | Disability status scale: (2)                               |                          |                                            |                     |
| SY   | 14  | Female | Functional systems: pyramidal function 2, brain-stem function 2 | (11)                     | (5)                                     | Improved           |
|      |     |        | Functional systems: sensory function 2, visual function 5 |                          |                                            |                     |
|      |     |        | Disability status scale: (2)                               |                          |                                            |                     |
| TY   | 23  | Male   | Functional systems: pyramidal function 1, cerebellar function 2 | (5)                       | (3)                                      | Improved           |
|      |     |        | Functional systems: brain-stem function 2                  |                          |                                            |                     |
|      |     |        | Disability status scale: (2)                               |                          |                                            |                     |
| IT   | 28  | Female | Functional systems: pyramidal function 2, brain-stem function 2 | (8)                       | (8)                                      | Unchanged           |
|      |     |        | Functional systems: sensory function 3, bladder function 1 |                          |                                            |                     |
|      |     |        | Disability status scale: (3)                               |                          |                                            |                     |
| WY   | 33  | Female | Functional systems: pyramidal function 3, sensory function 3 | (8)                       | (8)                                      | Unchanged           |
|      |     |        | Functional systems: bladder function 2                     |                          |                                            |                     |
|      |     |        | Disability status scale: (3)                               |                          |                                            |                     |
| TM   | 45  | Female | Functional systems: pyramidal function 5, sensory function 4 | (16)                     | (15)                                     | Improved            |
|      |     |        | Functional systems: bladder function 3, visual function 4   |                          |                                            |                     |
|      |     |        | Disability status scale: (7)                               |                          |                                            |                     |
| YO   | 32  | Male   | Functional systems: pyramidal function 2, cerebellar function 3 | (10)                     | (8)                                      | Improved           |
|      |     |        | Functional systems: brain-stem function 2                  |                          |                                            |                     |
|      |     |        | Disability status scale: (3)                               |                          |                                            |                     |
|      |     |        | Functional systems: sensory function 1, mental function 2   |                          |                                            |                     |
|      |     |        | Disability status scale: (3)                               |                          |                                            |                     |
Table 5. Effects of anti-measles colostrum on MS patients

| Colostrum          | High NT titre to measles virus (512–5120) | Low NT titre to measles virus (8–32) | Negative NT titre to measles virus (< 8) |
|--------------------|-------------------------------------------|-------------------------------------|----------------------------------------|
| Total recipients   | 7                                         | 8                                   | 5                                      |
| Improved cases     | 5*                                        | 5*                                  | 0                                      |
| Unchanged cases    | 2                                         | 3                                   | 2                                      |
| Worsened cases     | 0                                         | 0                                   | 3                                      |

*(P < 0.05)

Discussion

The aetiology of MS is still unknown and there is no specific treatment. Steroid hormones have been commonly used for exacerbations but have severe side-effects. Jacobs et al. [5] reported that intrathecal interferon reduced exacerbations of MS, but serial lumbar injections of interferon are painful. Mertin et al. [6] reported on the marginally beneficial effect of immunosuppressives (azathiopurine, antilymphocyte globulin and prednisolone), which were especially effective for HLA-A3-positive patients. However, immunosuppressive treatments also cause various side-effects. On the other hand, our oral colostrum administration did not cause any side-effects. Present data show that colostral non-fat milk containing lactoglobulin with NT titre to measles virus seems to hinder the clinical course of MS. Recently, Watanabe et al. [11] reported that infecting rats with murine coronavirus JHM led to the development of demyelinating encephalomyelitis several weeks to months post infection. Lymphocytes from these diseased Lewis rats were restimulated with basic myelin protein and adoptive transfer of these cells led to lesions resembling those of experimental allergic encephalomyelitis in recipients. This model demonstrates that a virus infection in CNS tissue is capable of initiating an auto-immune response, which may be of pathogenic importance.

We would like to propose that MS is also an auto-immune disease triggered by a morbillivirus infection in the small intestine.

Acknowledgements. This work was supported in part by a Research Grant for Slow Virus Infection from the Ministry of Health and Welfare of Japan and a grant from the Sendai Institute of Microbiology.

References

1. Bluestein HG, Zeigler NJ (1975) Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 57:509–516
2. Bresnihan B, Oliver M, Grigor R, Hughes GRV (1977) Brain reactivity of lymphocytotoxic antibodies in systemic lupus erythematosus with or without cerebral involvement. Clin Exp Immunol 30:333–337
3. Ebina T, Tsukamoto T, Suzuki H, Takase S, Itahara K, Ishida N (1979) Measles virus in jejunum of patients with multiple sclerosis. Lancet I:99

4. Ebina T, Sato A, Umezu K, Ishida N, Ohyama S, Oizumi A, Aikawa K, Katagiri S, Katsushima N, Imai A, Kitaoka S, Suzuki H, Konno T (1983) Prevention of rotavirus infection by cow colostrum containing antibody against human rotavirus. Lancet II:1029–1030

5. Jacobs L, O'Malley, J, Freeman A, Ekes R (1981) Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214:1026–1028

6. Mertin J, Rudge P, Kremer M, Healey MJR, Knight SC, Compston A, Batchelor JR, Thompson EJ, Halliday AM, Denman M, Medawar PB (1982) Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet II:351–353

7. Prasad I, Broome JD, Pertschuk LP, Gupta J, Cook AW (1977) Recovery of para-myxovirus from the jejunum of patients with multiple sclerosis. Lancet I:1117–1118

8. Schumacher GA, Beebe G, Kibler RF (1965) Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122:552–568

9. Sullivan JL, Barry DW, Lucas SL, Albrecht P (1975) Measles infection of human mononuclear cells I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med 142:773–784

10. Tsukamoto T, Ebina T, Takase S, Itahara K, Ishida N (1982) Increased frequency of lymphocytotoxic antibodies in patients with multiple sclerosis correlated with disease activity. Tohoku J Exp Med 136:121–128

11. Watanabe R, Wege H, ter Meuler V (1983) Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis. Nature 305:150–153

12. Winfield JB, Winchester RJ, Wernet P, Fu SM, Kunkel MG (1975) Nature of cold reactive antibodies to lymphocyte surface determinants in systemic lupus erythematosus. Arthritis Rheum 18:1–8

Received June 27, 1984